222 related articles for article (PubMed ID: 15896923)
21. A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2.
Mainou-Fowler T; Overman LM; Dignum H; Wood K; Crosier S; Angus B; Proctor SJ; Anderson JJ
Int J Oncol; 2008 Jan; 32(1):59-68. PubMed ID: 18097543
[TBL] [Abstract][Full Text] [Related]
22. p53 antibodies in patients with various types of cancer: assay, identification, and characterization.
Lubin R; Schlichtholz B; Teillaud JL; Garay E; Bussel A; Wild CP
Clin Cancer Res; 1995 Dec; 1(12):1463-9. PubMed ID: 9815945
[TBL] [Abstract][Full Text] [Related]
23. Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma.
Himoto T; Kuriyama S; Zhang JY; Chan EK; Kimura Y; Masaki T; Uchida N; Nishioka M; Tan EM
Int J Oncol; 2005 Oct; 27(4):1079-85. PubMed ID: 16142326
[TBL] [Abstract][Full Text] [Related]
24. Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas.
Forslund A; Kressner U; Lindmark G; Inganäs M; Lundholm K
Int J Oncol; 2001 Sep; 19(3):501-6. PubMed ID: 11494027
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors.
Nagaraj S; Pisarev V; Kinarsky L; Sherman S; Muro-Cacho C; Altieri DC; Gabrilovich DI
J Immunother; 2007; 30(2):169-79. PubMed ID: 17471164
[TBL] [Abstract][Full Text] [Related]
26. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
Gao RJ; Bao HZ; Yang Q; Cong Q; Song JN; Wang L
Breast Cancer Res Treat; 2005 Sep; 93(2):111-5. PubMed ID: 16187230
[TBL] [Abstract][Full Text] [Related]
27. Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer.
Nakano J; Huang CL; Liu D; Ueno M; Sumitomo S; Yokomise H
Int J Oncol; 2005 Nov; 27(5):1215-21. PubMed ID: 16211215
[TBL] [Abstract][Full Text] [Related]
28. Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer.
Gadducci A; Ferdeghini M; Buttitta F; Fanucchi A; Annicchiarico C; Prontera C; Bevilacqua G; Genazzani AR
Anticancer Res; 1996; 16(6B):3519-23. PubMed ID: 9042215
[TBL] [Abstract][Full Text] [Related]
29. [Clinical importance of serum anti-p53 antibodies as tumor markers].
Sakai H; Okamoto E
Rinsho Byori; 2002 Oct; 50(10):970-5. PubMed ID: 12451677
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
31. p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.
Creaney J; McLaren BM; Stevenson S; Musk AW; de Klerk N; Robinson BW; Lake RA
Br J Cancer; 2001 Jan; 84(1):52-6. PubMed ID: 11139313
[TBL] [Abstract][Full Text] [Related]
32. Humoral p53 antibody response is a prognostic parameter in ovarian cancer.
Mayerhofer K; Tempfer C; Kucera E; Hefler L; Zeisler H; Kainz C; Zeillinger R; Sliutz G
Anticancer Res; 1999; 19(1B):875-8. PubMed ID: 10216509
[TBL] [Abstract][Full Text] [Related]
33. Autoantibodies to survivin in patients with chronic hepatitis and hepatocellular carcinoma.
Yagihashi A; Asanuma K; Kobayashi D; Tsuji N; Torigoe T; Sato N; Watanabe N
Autoimmunity; 2005 Sep; 38(6):445-8. PubMed ID: 16278150
[TBL] [Abstract][Full Text] [Related]
34. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group.
Shimada H; Ochiai T; Nomura F;
Cancer; 2003 Feb; 97(3):682-9. PubMed ID: 12548611
[TBL] [Abstract][Full Text] [Related]
35. Anti-P53 antibodies in Brazilian brain tumor patients.
Fonseca RF; Kawamura MT; Oliveira JA; Teixeira A; Alves G; Carvalho Mda G
Genet Mol Res; 2003 Jun; 2(2):185-90. PubMed ID: 14966683
[TBL] [Abstract][Full Text] [Related]
36. Rapid and sensitive immunomagnetic-electrochemiluminescent detection of p53 antibodies in human serum.
Yan G; Xing D; Tan S; Chen Q
J Immunol Methods; 2004 May; 288(1-2):47-54. PubMed ID: 15183084
[TBL] [Abstract][Full Text] [Related]
37. [IL-6, p53 and proto-oncogene c-myc play different roles as biological markers of plasma cell dyscrasias].
Alvino S; Marcucci M; Canzoniere D; Mosiello A; Del Monte G; Venturo I; Rinaldi M; Gandolfo GM; Lopez M; Greco C
Clin Ter; 1999; 150(3):197-202. PubMed ID: 10528431
[TBL] [Abstract][Full Text] [Related]
38. p53 autoantibodies from patients with colorectal cancer recognize common epitopes in the N- or C-terminus of p53.
Saleh J; Kreissler-Haag D; Montenarh M
Int J Oncol; 2004 Oct; 25(4):1149-55. PubMed ID: 15375567
[TBL] [Abstract][Full Text] [Related]
39. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer.
Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341
[TBL] [Abstract][Full Text] [Related]
40. p53 Antibodies in the sera of patients with various types of cancer: a review.
Soussi T
Cancer Res; 2000 Apr; 60(7):1777-88. PubMed ID: 10766157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
